SCHEMBL25852154

SCHEMBL25852154

CC(C)N(Cc1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
LMNA P02545 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
HSD17B10 Q99714 1/20 0.49
AKT1 P31749 2/20 0.48
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
ATM Q13315 2/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7320870 0.89 MEN1 (0.50) KMT2AMEN1LMNAL3MBTL1ALDH1A1
SCHEMBL4526992 0.88 L3MBTL1 (0.50) KMT2AMEN1LMNAL3MBTL1ALDH1A1
SCHEMBL31667777 0.88 L3MBTL1 (0.50) KMT2AMEN1LMNAL3MBTL1ALDH1A1
SCHEMBL3117862 0.87 MEN1 (0.44) KMT2AMEN1ALDH1A1HDAC3HDAC1
SCHEMBL25934543 0.87 L3MBTL1 (0.49) KMT2AMEN1LMNAL3MBTL1ALDH1A1
SCHEMBL13825505 0.86 MEN1 (0.43) KMT2AMEN1LMNAL3MBTL1ALDH1A1
SCHEMBL13215086 0.86 AKT1 (0.48) KMT2AMEN1LMNAL3MBTL1ALDH1A1
SCHEMBL23746079 0.85 MEP1B (0.46) KMT2AMEN1
SCHEMBL2578593 0.85 MEN1 (0.42) KMT2AMEN1LMNAL3MBTL1ALDH1A1
SCHEMBL3143341 0.85 MEN1 (0.42) KMT2AMEN1LMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239830-A1 METHODS OF PREPARING CARBANUCLEOSIDES USING AMIDES ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2024-07-18 US disclosed
US-20240239830-A1 METHODS OF PREPARING CARBANUCLEOSIDES USING AMIDES ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2024-07-18 US disclosed
US-11697666-B2 Methods of preparing carbanucleosides using amides GILEAD SCIENCES, INC. (US) 2023-07-11 US disclosed
US-11697666-B2 Methods of preparing carbanucleosides using amides GILEAD SCIENCES, INC. (US) 2023-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11697666-B2 Methods of preparing carbanucleosides using amides NCL, DUT, POLN KMT2A 1870/4885MEN1 1682/4885LMNA 154/4885
US-20240239830-A1 METHODS OF PREPARING CARBANUCLEOSIDES USING AMIDES NCL, DUT, POLN KMT2A 1870/4885MEN1 1682/4885LMNA 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.